- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Analogic taps Miller as CEO
A new leader has been named at Analogic. Company founder, board chairman, and CEO Bernard M. Gordon announced Jan. 25 that Thomas J. Miller Jr., will assume the role of CEO effective Feb 1. Gordon will remain as board chairman.Gordon, who founded
A new leader has been named at Analogic. Company founder, board chairman, and CEO Bernard M. Gordon announced Jan. 25 that Thomas J. Miller Jr., will assume the role of CEO effective Feb 1. Gordon will remain as board chairman.
Gordon, who founded Analogic in 1969, is an R&D icon, having developed numerous technologies, notably the first high-speed analog-to-digital converter. He was awarded the National Medal of Technology in 1986. Miller has served as president and COO of Analogic for the past 15 months. During this time he developed and began implementing a five-year strategic plan. Prior to joining Analogic, Miller had been president and CEO of Carl Zeiss, Inc., world general manager of Carl Zeiss Medical Group, and group vice president of imaging systems for Siemens Medical Systems' North American operations.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
